Conquer Cancer Announces Two Recipients of Research Grants From the Lobular Breast Cancer Alliance
ALEXANDRIA, Virginia — Conquer Cancer®, the ASCO Foundation, in collaboration with the Lobular Breast Cancer Alliance, has awarded two grants to support innovative research focused on improving treatment and care for patients with invasive lobular carcinoma (ILC).
The two recipients of the Lobular Breast Cancer Alliance Invasive Lobular Carcinoma Research Grants are:
Manisha Bahl, MD, MPH, FSBI (Massachusetts General Hospital) received the 2024 Lobular Breast Cancer Alliance and Sarah Bieze Invasive Lobular Carcinoma Research Grant for her research, “Improving Detection of Invasive Lobular Carcinoma on Digital Breast Tomosynthesis and Reducing False-Negative Rates with Artificial Intelligence.”
Higinio Dopeso, PhD (Memorial Sloan Kettering Cancer Center) received the 2024 Lobular Breast Cancer Alliance and Deb Mueller Foundation Fund Invasive Lobular Carcinoma Research Grant in honor of Dr. Deborah L. Mueller for his research, “Deciphering Molecular Mechanisms and Therapeutic Vulnerabilities in RHOA-Altered Invasive Lobular Breast Cancer.”
ILC, also known as lobular breast cancer, is the second most common histological subtype of breast cancer. It has a unique biology, a distinct pattern of behavior, and is a challenging disease to manage and treat. There is a critical need to advance understanding of this disease and improve treatment and follow-up care options for patients living with it. These one-year grants will provide $50,000 in pilot funding.
As the only organization in the U.S. dedicated to ILC, the Lobular Breast Cancer Alliance’s mission is to raise awareness about the disease; to be the go-to source for information on ILC studies, clinical trials, and educational tools; to foster partnerships among patients, scientists, clinicians, and breast cancer organizations to increase dialogue about ILC and research advocacy; and to fund vital ILC research.
These are grants from the Lobular Breast Cancer Alliance, with Conquer Cancer serving as the lead organization in implementing and administering the grant through EveryGrant®.